Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TAZAROTENE

All products: Limited Use (codes 636)

Other products in the same Health Canada class (D05AX) — coverage varies; not interchangeable

  • Betamethasone dipropionate + calcipotriol (Dovobet): general benefit
  • Calcipotriol (Dovonex): limited Use 191
  • Calcitriol (Silkis): limited Use 191

Arazlo · DIN 02517868 · 0.045% w/w · Lot

Limited Use — Reason for Use code 636 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 636 required
Write on scriptLU code 636 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 636
Reason for Use code 636 For the treatment of acne vulgaris. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Arazlo · DIN 02517868 Manufacturer: Bausch Health Canada Inc.; listing date 2022-10-31 Health Canada: Marketed since 2021-09-16 · brand ARAZLO · ATC D05AX05 TAZAROTENE · form Lotion · route Topical · ingredients TAZAROTENE 0.045 %/W/W · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Arazlo: Formulary list price $1.4051/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.4051 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100721 · Verify on the e-Formulary ↗ (DIN 02517868)

Source record
DIN 02517868: Arazlo Raw flags: sec12=Y, sec3=Y Item: 849200008; group id 873; item number 2111; lccId 00362; manufacturer id BHC Source form: Lot; strength: 0.045% w/w Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.4051; ministry $1.4051 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02517868 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100721
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02517868
Shortage record checked 2026-09-13T08:10:21.292534+00:00

HALOBETASOL PROPIONATE & TAZAROTENE

All products: general benefit

Other products in the same Health Canada class (D05AX) — coverage varies; not interchangeable

  • Betamethasone dipropionate + calcipotriol (Dovobet): general benefit
  • Calcipotriol (Dovonex): limited Use 191
  • Calcitriol (Silkis): limited Use 191

Duobrii · DIN 02499967 · 0.01% & 0.045% · Lot

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Duobrii · DIN 02499967 Manufacturer: Bausch Health Canada Inc.; listing date 2022-01-31 Health Canada: Marketed since 2020-08-04 · brand DUOBRII · ATC D05AX05 TAZAROTENE, D05AX05 TAZAROTENE · form Lotion · route Topical · ingredients TAZAROTENE 0.045 %/W/W, HALOBETASOL PROPIONATE 0.01 %/W/W · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Duobrii: Formulary list price $1.9300/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.9300 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98967 · Verify on the e-Formulary ↗ (DIN 02499967)

Source record
DIN 02499967: Duobrii Raw flags: sec3=Y Item: 849200006; group id 872; item number 2110; lccId None; manufacturer id BHC Source form: Lot; strength: 0.01% & 0.045% Recorded listing: General benefit Source prices (unrounded): $1.9300; ministry $1.9300 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02499967 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98967
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02499967
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (84:00 SKIN AND MUCOUS MEMBRANE PREPARATIONS) and how they are covered

Matched class: 84:00 SKIN AND MUCOUS MEMBRANE PREPARATIONS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ACITRETIN, AZELAIC ACID, BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE, CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE, DIMETHICONE., FLUOROURACIL, FUSIDIC ACID, HALOBETASOL PROPIONATE, ISOPROPYL MYRISTATE, ISOTRETINOIN, METRONIDAZOLE & NYSTATIN, MICONAZOLE NITRATE, MOMETASONE FUROATE, MUPIROCIN CALCIUM, PERMETHRIN, PYRETHRINS & PIPERONYL BUTOXIDE, SILVER SULFADIAZINE, SODIUM FUSIDATE, TERBINAFINE HCL, ZINC SULFATE Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, CLOTRIMAZOLE, COLLAGENASE, DESONIDE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE, KETOCONAZOLE, METRONIDAZOLE, MUPIROCIN, NYSTATIN, TERCONAZOLE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE 84:00 SKIN AND MUCOUS MEMBRANE PREPARATIONS

BIMEKIZUMAB

· 4 products · Limited Use, codes 641 · strengths: 160mg/mL, 320mg/2mL · Inj Sol-1mL Pref Autoinj (Preservative-Free), Inj Sol-1mL Pref Syr (Preservative-Free), Inj Sol-2mL Pref Autoinj (Preservative-Free), Inj Sol-2mL Pref Syr (Preservative-Free)

GUSELKUMAB

· 2 products · Limited Use, codes 658 · strengths: 100mg/mL · Inj Sol-1mL Autoinj (Preservative-Free), Inj Sol-1mL Pref Syr (Preservative-Free)

TILDRAKIZUMAB

· 1 products · Limited Use, codes 629 · strengths: 100mg/mL · Inj Sol-1mL Pref Syr (Preservative-Free)

ACYCLOVIR

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5% · Top Oint Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:00 84:04:04 Antibiotics

CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE

· 4 products · General benefit · strengths: 1% & 5% · Gel, Top Gel

FUSIDIC ACID

· 2 products · General benefit · strengths: 2% · Cr

MUPIROCIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Oint

MUPIROCIN CALCIUM

· 1 products · General benefit · strengths: 2% w/w · Cr

SODIUM FUSIDATE

· 2 products · General benefit · strengths: 2% · Oint

CLINDAMYCIN PHOSPHATE & ADAPALENE & BENZOYL PEROXIDE

· 1 products · Limited Use, codes 724 · strengths: 1.2% w/w & 0.15% w/w & 3.1% w/w · Top Gel Pump

CLINDAMYCIN

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% · Top Sol Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:04 84:04:08 Fungicides

CLOTRIMAZOLE

· 7 products · General benefit (6), Listed, not a benefit (1) · strengths: 10mg/g, 500mg & 1%, 20mg/g · Cr, Tab & Cr, Vag Cr-App Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:08 and 52 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: acne
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CLINDAMYCIN · Off-Formulary Interchangeable, not an ODB benefit INDICATIONS AND CLINICAL USE Taro-Clindamycin 1% (clindamycin phosphate) is indicated for the treatment of acne vulgaris. PM: https://pdf.hres.ca/dpd_pm/00058691.PDF; date not captured; DIN 02266938; fetched 2026-09-10 Product monograph CLINDAMYCIN PHOSPHATE & ADAPALENE & BENZOYL PEROXIDE · Limited Use, codes 724 1 INDICATIONS CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. PM: https://pdf.hres.ca/dpd_pm/00076715.PDF; date AUG 14, 2024; DIN 02550423; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS ARAZLO™ (tazarotene lotion), is indicated for: • For the topical treatment of acne vulgaris in patients 10 years of age and older. 1.1 Pediatrics Pediatrics (≥ 10 years of age) The safety and efficacy of ARAZLO in pediatric patients (10 years of age and older) has been established. In a clinical pharmacokinetic study, systemic exposure of tazarotene and tazarotenic acid were substantially higher in subjects 10 to <12 years of age than subjects ≥12 years of age due to higher surface area to volume ratio of younger subjects. Therefore, Health Canada recommends that application of ARAZLO in this age group be limited to the face (see 7 WARNINGS AND PRECAUTIONS; 10 ACTION AND CLINICAL PHARMACOLOGY; 14 CLINICAL TRIALS). Safety and efficacy of ARAZLO in children below the age of 10 years has not been established. Therefore, Health Canada has not authorized an indication in pediatric patients less than 10 years of age. 1.2 Geriatrics Geriatrics (> 65 years of age) A limited number of subjects aged > 65 years have been treated with ARAZLO in clinical trials, therefore the safety and efficacy have not been established in this patient populat… https://pdf.hres.ca/dpd_pm/00082613.PDF PM date: NOV 28, 2025 Source product: ARAZLO; DIN 02517868; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS DUOBRII (halobetasol propionate and tazarotene lotion), is indicated for: • Improving the signs and symptoms of plaque psoriasis in adult patients with moderate to severe plaque psoriasis. 1.1 Pediatrics Pediatrics (under the age of 18 years) The safety and efficacy of DUOBRII in pediatric patients have not been established; therefore, DUOBRII is not indicated for pediatric use (see WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics). 1.2 Geriatrics Geriatrics (> 65 years of age) A limited number of subjects aged > 65 years have been treated with DUOBRII in clinical trials, therefore the safety and efficacy have not been established in this patient population (see WARNINGS AND PRECAUTIONS, Special Populations, Geriatrics). https://pdf.hres.ca/dpd_pm/00082162.PDF PM date: June 17, 2022 Source product: DUOBRII; DIN 02499967; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.